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gp41The detailed interactions between antibodies and the HIV-1 envelope protein that lead to neutralization are
not well deﬁned. Here, we show that several conservative substitutions in the envelope gp41 led to a ~100
fold increase in neutralization sensitivity to monoclonal antibodies (MAbs) that target gp41: 4E10 and 2F5.
Substitution at position 675 alone did not impact neutralization susceptibility to MAbs that recognize more
distal sites in gp120 (b12, VRC01, PG9). However, changes at position 675 in conjunction with Thr to Ala
at position 569 increased the neutralization sensitivity to all gp41 and gp120 MAbs and plasma, in some
cases by more than 1000-fold. Interestingly, the T569A change had a dramatic effect on b12 binding, but
no effect on neutralization sensitivity. This ﬁnding suggests that antibody neutralization may occur through
a multi-step pathway that includes distinct changes in envelope conformation that may affect binding but not
neutralization susceptibility.logy, Fred Hutchinson Cancer
, Seattle, WA 98109-1024, USA.
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Neutralizing antibodies (NAbs) play an important role in driving
viral escape during HIV-1 infection (reviewed in (Burton et al., 2005)).
HIV-1 speciﬁc NAb also have the potential to contribute to protection
from infection, as evidenced by studies showing that passively adminis-
tered HIV-1 speciﬁc monoclonal antibodies (MAbs) can prevent SHIV
infection in non-human primates (reviewed in (Hu, 2005; Mascola,
2003)). However, antibodies capable of neutralizing a diverse spectrum
of HIV-1 variants will be needed to achieve signiﬁcant protection
against circulating strains of HIV-1.While there are someHIV-1 speciﬁc
NAbs that have broad speciﬁcity (Scheid et al., 2011;Walker et al., 2009,
2011; Wu et al., 2010, 2011), many virus isolates are not recognized by
such MAbs, even those that target conserved regions of the virus (Blish
et al., 2007, 2008, 2010; Scheid et al., 2011; Walker et al., 2009, 2011;
Wu et al., 2010, 2011). Themolecular basis for differences in neutraliza-
tion sensitivity, especially in cases where the amino acid changes are
outside of known epitope targets, remains poorly deﬁned.
The envelope protein (Env) surface unit (gp120) and the transmem-
brane protein (gp41) are both targets of NAbs, including several MAbs
that have been studied in some detail (reviewed in (Burton et al., 2004;
Zolla-Pazner and Cardozo, 2010)). Two of the most intensively studied
MAbs, 2F5 and4E10, target adjacent conserved epitopes in themembrane
proximal external region (MPER) of gp41: ELDKWA and NWF(D/N)IT,
respectively; (Muster et al., 1993; Zwick et al., 2001). These MAbs bindto their peptide epitope target (Cardoso et al., 2005; Ofek et al., 2004),
and they also bind weakly to membrane lipids but this binding alone
does not induce neutralization (Julien et al., 2010; Xu et al., 2010).
There are also multiple antibody targets in the surface unit gp120.
The IgG1 MAb b12 targets a discontinuous epitope overlapping the
CD4 binding pocket (Burton et al., 1994; Roben et al., 1994). MAb b12
neutralizes a majority of subtype B variants (Binley et al., 2004; Burton
et al., 1994), but fewer variants of other subtypes (Blish et al., 2007,
2009;Wu et al., 2006). More recently, VRC01, another MAb that targets
the CD4 binding site, has been identiﬁed; VRC01 exhibits increased
breadth and potency compared to b12 (Wu et al., 2010). A collection
of relatedMAbs targeted to a different epitope in gp120 butwith similar
breadth as VRC01, have also been described recently (Walker et al.,
2009). TheseMAbs, PG9 and PG16, recognize an epitope formed by con-
served regions of V2 and V3 (Walker et al., 2009).
Early studies of antibody binding to HIV envelope focused on lab-
adapted HIV-1 envelopes variants derived from virus grown in cell lines,
which generally use the CXCR4 receptor. The study of these lab-adapted
envelopes suggested that antibody neutralization correlated with bind-
ing to the envelope monomer (Parren et al., 1998a; Roben et al., 1994;
Sattentau and Moore, 1995). Results of subsequent studies of envelope
variants fromviruses grown in primary cells, including CCR5-tropic var-
iants that aremore common in HIV-1 infection, suggested that antibody
binding to monomeric envelope did not reliably predict neutralization
potential (Fouts et al., 1997). Binding to the oligomeric formof envelope
found on the virion has been correlated with neutralization sensitivity
(Fouts et al., 1997; Sattentau and Moore, 1995; Stamatatos and
Cheng-Mayer, 1995; Sullivan et al., 1995). However, there are numer-
ous examples of MAbs that bind to virion-associated envelope protein,
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ing alone is not sufﬁcient to promote neutralization (Cavacini and Posner,
2004; Herrera et al., 2005; Leaman et al., 2010; Moore et al., 2006;
Nyambi et al., 2000; Parren et al., 1998b). There is also evidence for bind-
ing between some trimeric envelope proteins and non-neutralizing anti-
bodies in virion-capture assays (Poignard et al., 2003). Some of this
binding can be explained by the potential of non-neutralizing antibodies
to bind uncleaved envelope— an interaction that would not impact infec-
tivity (Dey et al., 2009; Pancera andWyatt, 2005). Thus, in examining dif-
ferences in binding, the amounts of cleaved versus uncleaved envelope
protein must be considered. Because many of the most detailed studies
have focused on laboratory-adapted isolates or primary isolates obtained
after culture, less is known regarding the NAb-binding properties of en-
velope variants obtained directly from infected individuals.
In a study of two closely related HIV-1 Env variants (Q461e2 and
Q461d1) cloned directly from the blood of a subtype-A-infected indi-
vidual, two amino acid differences were identiﬁed that altered neutral-
ization sensitivity to a variety of NAb (Blish et al., 2008). Speciﬁcally,
two changes in gp41, a T to A at position 569 (T569A) and an I to V
change at position 675 (I675V) increased neutralization sensitivity to
a variety of NAbs, including those that target gp41 as well as those
that recognize distal sites in gp120 (Blish et al., 2008). HIV envelope
mutations that impact neutralization susceptibility at distal sites had
been reported prior to this study (Back et al., 1993; Klasse et al., 1993;
Park et al., 1998, 2000; Reitz et al., 1988; Thali et al., 1994; Wilson et
al., 1990; Zwick et al., 2005) and more recently (O'rourke et al., 2009;
Shen et al., 2010) although these amino acid changes typically did not
demonstrate the magnitude and/or breadth of the effects caused by
the T569A and I675V changes. The T569A and I675V changes showed
similar effects on neutralization sensitivity when introduced into
other envelope variants, including variants from different subtypes
(Blish et al., 2008; Wu et al., 2009). These ﬁndings suggest that the
two amino acid positions in gp41 have a global impact on envelope
structure that results in better exposure of epitopes throughout the pro-
tein. In this study,we took advantage of the differences in neutralization
sensitivities conferred by these amino acid changes to examine how
speciﬁc changes at distal sites impact antibody binding and neutraliza-
tion. Our results suggest that for some antibodies the speciﬁc amino
acid change have a concordant effect on both envelope protein binding
and virus neutralization. However, in other cases, the effects of each
change on binding and neutralization could be separated, suggesting a
two-component model for the interaction of these amino acids, one to
promote binding and the other to increase neutralization susceptibility.
Results
Characterization of the neutralization sensitivities of Q461 variant Envs
The neutralization sensitivity of the original Q461 variants was
compared to variants engineered to contain other changes at position
675, which resides within the 4E10 epitope [Fig. 1; (Blish et al.,HR1
Fig. 1. Sequence changes of the Q461e2 mutants. The amino acid sequence of the parental, w
Differences in the mutant envelope variants are indicated. The clone names are shown to th
membrane proximal external region of gp41.2008)]. Similar to previously published results, the combination of a
change fromThr to Ala at position 569 and Ile to Val at position 675 intro-
duced into the neutralization-resistant Q461e2 (Q461e2TAIV) resulted in
a dramatic increase in neutralization sensitivity to various NAbs, includ-
ing both MAbs and polyclonal NAbs in plasma pooled from HIV-positive
individuals (Table 1). The T569A change alone had little impact on neu-
tralization sensitivity: neither the pooled plasma nor MAb b12 achieved
50% neutralization of Q461e2TA while the MAbs 4E10 and 2F5 resulted
in detectable but modest neutralization (IC50 values of 18.8 and
12.6 μg/ml, respectively). Virus with only the Ile to Val change at position
675 (Q461e2IV) showed N250-fold increase in neutralization sensitivity
to the gp41-directed MAbs, 4E10 and 2 F5 (IC50 values of 0.1 μg/ml)
when compared with Q461e2. However, this virus was resistant to both
MAbs directed to gp120 as well as to the NAbs in pooled plasma as ob-
served previously (Blish et al., 2008).
To examine whether the increase in neutralization sensitivity of the
I675V variant to gp41-speciﬁc MAbs was due to the loss of an Ile or the
presence of a Val at position 675,we investigated the neutralization sen-
sitivity of Q461e2-derived viruses with other uncharged amino acids at
this position, either alone or in combination with the T569A change. Vi-
ruses with a change from Ile to either an Ala or Thr at position 675
(Q461e2IA and Q461e2IT, respectively) showed similar neutralization
proﬁles as Q461e2IV with IC50 values ranging from 0.04 to 0.3 μg/ml
with 4E10 and 2F5. As observed for Q461e2IV, there was no detectable
neutralization of Q461e2IA or Q461e2IT by either b12 or the pooled
plasma at the highest concentrations tested (25 μg/ml for b12 and
1:50 dilution for the plasma pool).
Viruses with a change from Ile to either an Ala or Thr at position 675
paired with the T569A change (Q461e2TAIA and Q461e2TAIT, respec-
tively), also showed similar neutralization proﬁles to a variant encoding
the Val at 675 (Q461e2TAIV). The Q461e2TAIV, Q461e2TAIA, and
Q461e2TAIT variants were ~6-fold more sensitive to neutralization by
the gp41-directed MAbs 2 F5 and 4E10 than the corresponding variants
that did not have the secondary mutation at position 569, with IC50
values ranging from less than 0.02–0.03 μg/ml. There was also an in-
crease of ~10-fold or more in neutralization sensitivity to b12 of viruses
with bothmutations (Q461e2TAIA and Q461e2TAIT) compared to virus-
es with only the mutation at position 675 (Q461e2IA and Q461e2IT); in
this case, the IC50 values ranged from 1.2 to 3.3 μg/ml. The effect of the
combination of mutations at positions 569 and 675wasmuchmore dra-
matic when tested against the neutralization activity of the plasma pool:
no detectable neutralization was observed with the pooled plasma
against the viruses with either of the single mutations at positions 569
or 675, whereas the IC50 values ranged from a dilution of 1547–5587
for the viruses with both changes.
In all cases, the IC50 values were similar (within 4-fold) when com-
paring viruses with these three different amino acid changes at 675, ei-
ther alone or in combinationwith the Thr to Ala change at position 569.
Thus, the presence of an Ile at position 675 is speciﬁcally associatedwith
a neutralization-resistant phenotype; a variety of other amino acids at
that position can confer neutralization susceptibility.HR2 MPER
ild type Q461e2 in the relevant regions of the transmembrane domain, gp41, is shown.
e left. HR1 and HR2 refer to heptad repeats 1 and 2, respectively and MPER refers to the
Table 1
IC50 values for the MAb and plasma against pseudoviruses with the Q461 Env mutants.
Q461e2
mutant
MAb Plasma
poola
4E10a 2F5a b12a
e2 N25 N25 N25 b1:50
TA 18.8 12.6 N25 b1:50
IV 0.1 0.1 N25 b1:50
IA 0.1 0.04 N25 b1:50
IT 0.3 0.1 N25 b1:50
TAIV 0.03 b0.02 3.3 1547
TAIA b0.02 b0.02 2.7 2080
TAIT b0.02 b0.02 1.2 5587
a All values are concentraions of the MAb (in μg/ml) or reciprocal dilutions of the
plasma required to achieve 50% neutralization. IC50 values are the arithemetic mean
averages of three independent experiments performed in triplicate.
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To determine if the differences in neutralization sensitivitieswere as-
sociated with differences in the levels Env on the viral particles, we per-
formed western blots on the puriﬁed pseudoviral particles and
quantiﬁed the Env and Gag p24 protein levels using a rabbit polyclonal
antisera, which recognizes both uncleaved (gp160) and cleaved
(gp120) forms of Env (Doria-Rose et al., 2005) and an anti-p24-speciﬁc
MAb (Fig. 2). Themajority of Env detected was uncleaved gp160 protein
(Fig. 2a). In general, viruses encoding the Thr to Ala change at position
569 had the least amount of cleaved Env, whether T569A was alone or
in combination with the second change at 675. In some cases, such as
TAIT, the percent cleavage may be slightly overestimated because the
signal for the uncleaved envelope is near saturation for that Env. Thus,
thepercentage of cleaved Env ranged from≤21–26% among the variants
encoding Ala at 569, compared to 39–50% among viruses with a Thr at
position 569.
The levels of total Env protein on pseudoviruses derived from themu-
tant envelopes varied by less than 4-fold from that of the parental
Q461e2 (Fig. 2b). The neutralization sensitive virus Q461e2TAIT had the
highest amount of Env (≥3.5-fold more than Q461e2), mostly in the
uncleaved form. Another neutralization-sensitive variant, Q461e2TAIV,
along with the neutralization-resistant parental virus, Q461e2, had the
lowest levels of total Env protein. Similar results were observed for
uncleaved Env (gp160; Figs. 2a and b). In the case of cleaved Env,
which is the presumed functional target of the neutralizing antibodies,
the levels were within ~2-fold to those of the parental Q461e2 virus for
the other viruses. Q461e2TAIV had the lowest amounts of cleaved Env
and Q461e2TAIT had the greatest amounts of cleaved Env .
Similar patterns of expression were observed when the Env levels
were normalized to Gag (p24) protein (Fig. 2c). The amounts of total
Env/p24 varied ~2-fold compared to Q461e2; Q461e2TAIT had the
greatest amount of total Env/p24 (~2-fold more than Q461e2) and
Q461e2TAIA had the least amount of total Env/p24 (~half the amount
of Q461e2). The amounts of cleaved Env/p24 was highest for
Q461e2IT (~2-fold more than Q461e2) and lowest for Q461e2TAIA
(~one-third that of Q461e2). Overall, therewas no apparent correlation
between the patterns of Env expression and the neutralization proper-
ties of the virus.
Effect of amino acid changes at position 569 and 675 on sensitivity to
broadly neutralizing MAbs, PG9 and VRC01
Since the ﬁrst description of the effect of the T569A and I675V amino
acid changes on neutralization sensitivity (Blish et al., 2007), several po-
tent MAbs have been isolated, notably VRC01 and PG9 (Walker et al.,
2009; Wu et al., 2010). To determine if the amino acid changes at 569
and 675, which are outside of these MAb recognition sites, impactneutralization sensitivity, we examined the ability of the MAbs to neu-
tralize virus bearing the original neutralization-resistant Q461e2 Env
and associated mutants (Table 2). The pattern of neutralization suscep-
tibility with these MAbs was generally similar to that with other MAbs:
Q461e2wasmore difﬁcult to neutralize thanQ461e2TAIV. However, the
difference in neutralization sensitivity was relativelymodest. In the case
of PG9, 50% inhibition was not achieved for Q461e2 at the maximum
concentration tested (10 μg/ml). The MAb PG9 did neutralize
Q461e2TAIV with modest potency (IC50 2.6 μg/ml); and there was also
somedetectable neutralization of the variant bearing the T569Amutation
alone (IC50 7.2 μg/ml), but neutralizationwas not achieved at the highest
concentration tested (10 μg/ml) for the variant bearing Envwith a change
at position 675. Similar results were observed with VRC01: the combina-
tion of T569A and I675V increased neutralization susceptibility compared
to the parental Q461e2 (IC50 0.3 μg/ml and 1.6 μg/ml, respectively); the
individual mutants had an intermediate effect (Table 2).
Effect of mutations that alter neutralization sensitivity on binding to b12,
a MAb targeted to gp120
A ﬂow cytometric assay using 293T cells expressing the various Env
variants was performed to determine the binding properties of NAbs to
the Envmutants, and to examine whether themutations that confer en-
hanced neutralization sensitivity also increase binding to the sameNAbs.
IgG b12, which binds to an epitope overlapping the CD4 binding site in
gp120 (Burton et al., 1994; Roben et al., 1994), was used to probe the ef-
fects of the two gp41-associated changes onNAb binding at distal sites in
gp120. SF162, a highly neutralization-sensitive Env (Binley et al., 2004;
Saunders et al., 2005),was used as a positive control for theﬂow cytome-
try experiments. As shown in Fig. 3, b12 binding was evident by an in-
crease in ﬂuorescence of cells expressing SF162 Env compared to mock
transfected cells. There was no evidence of binding to cells transfected
with SIV Env, suggesting that the b12 binding was speciﬁc for HIV-1
Env. In the case of cells expressing Env variants encoding only the change
at position 675 (Q461e2IV, Q461e2IA, Q461e2IT), therewasno clear shift
in ﬂuorescence intensity in the presence of b12. However, cells expres-
sing the Env variant with the change from Thr to Ala at position 569
(Q461e2TA) showed a clear and reproducible shift in ﬂuorescence inten-
sity, indicating that this variant is capable of binding b12 MAb even
though it is not sensitive to neutralization by this NAb. The most pro-
nounced binding was observed with the neutralization-sensitive vari-
ants encoding both changes in the gp41 (Q461e2TAIV, Q461e2TAIA
andQ461e2TAIT), resulting in clear shifts in ﬂuorescence intensities sim-
ilar to that of cells expressing SF162 Env.
Env levels in cells used in these ﬂow cytometry experiments were
evaluated by western blot using a rabbit polyclonal antisera (Fig. 3b). As
seen previously, the envelope proteins of the subtype B envelope variant
SF162 have increased mobility compared to Q461e2, which is common
among HIV envelope variants because of differences in envelope length
and glycosylation (Blish et al., 2007). The overall levels of total Env
expressed in 293T cells were similar across all Q461e2 variants (within
2-fold), but there was variation up to ~5-fold in the fraction of Env that
was cleaved. Q461e2 had the highest percentage (~75%) of cleaved Env.
Cells expressing Env encoding the T569A change, either alone or in com-
binationwith a change at 675, had the smallest percentage of cleaved Env.
The percentage of cleaved Env ranged from~15–17% among cells expres-
sing Envs with an Ala at 569, compared to ~66–75% among the cells
expressing Env proteins with a Thr at position 569. The cells expressing
the envelope variants with the highest level of binding to b12 had the
highest levels of unprocessed Env and the lowest levels of Env gp120.
However, it is important to note that even for the 461e2 and I675 enve-
lope variants that did not bind b12 in this assay, there was a substantial
amount of unprocessed envelope, in some cases, similar (within 2-fold)
to the levels found in envelope variants that did bind b12 (compare
Q461e2IV andQ461e2TAIV). This suggests that differences in b12 binding
cannot simply be due to binding to unprocessed envelope protein.
Table 2
IC50 values for the MAbs PG9 and VRC01 against pseudoviruses with the Q461 Env
mutants.
Q461e2 mutant PG9a VRC01a
e2 N10 1.6
TA 7.2 0.7
IV 13.5 0.8
TAIV 2.6 0.3
a All values are concentraions of the MAb (in μg/ml) required to achieve 50% neutral-
ization. IC50 values are the arithemetic mean averages of three independent experi-
ments performed in triplicate.
Fig. 2. Western blot analyses of Env (i.e., gp160 and gp120) and Gag (i.e., p24) of Q461e2-associated pseudoviral supernatants. (A) Western blot of Q461e2-associated pseudoviral su-
pernatants probed with a combination of anti-Env polyclonal rabbit primary Ab, which recognizes uncleaved Env (i.e., gp160) and cleaved Env (i.e., gp120), and anti-p24 mouse Ab
for the detection of Gag (i.e., p24). The Env tested is shown above and the % Env cleavage is shown below. Percent cleavage was calculated as the amount of gp120/(gp120+gp160).
(B) Comparison of Env levels of mutants relative to Q461e2. For each variant (designated below bar graph) the total, cleaved, and uncleaved Env levels were calculated relative to
Q461e2, which thus has a level of 1. (C) Comparison of Env/p24 levels of mutants relative to Q461e2. For each variant (designated below the bar graph) the total, cleaved and uncleaved
Env levels divided by p24 levels are shown relative to Q461e2.
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protein, 2F5 and 4E10
We also examined the binding properties of the gp41-directed
MAbs, 2F5 and 4E10, using cells expressing the same panel of Env var-
iants. In the case of 2 F5, there was a subtle but reproducible shift in
ﬂuorescence for cells expressing the positive control, SF162 Env
(Fig. 4a). For the parental, neutralization-resistant Env Q461e2 and
the Q461e2TA variant, which is also relatively resistant to 2F5 neu-
tralization, the ﬂuorescence intensity of cells expressing these Envs
was similar to or just slightly greater than the ﬂuorescence intensity
of mock-transfected cells and cells expressing the SIV Env. There
was more signiﬁcant and consistent shift in ﬂuorescence intensity
for each of the viruses encoding a change from Ile at position 675,
Fig. 3. (A) Flow cytometry analysis of b12 binding to cells expressing Q461e2 Env variants. The gray shaded proﬁle denotes ﬂuorescence for cells transfected in the absence of plas-
mid (Mock transfected cells). The color designation for the ﬂuorescence proﬁle for the various Envs is shown within each panel. (B) Western blot of cells expressing the Q461e2-
associated Envs probed with an anti-Env polyclonal rabbit primary Ab, which recognizes uncleaved Env (i.e., gp160) and cleaved Env (i.e., gp120). The bands corresponding to
gp160 and gp120 are designated to the right. For each lane, the Env tested is shown above the blot, with the wild type (WT), parental Q461e2 indicated. The percent of Env cleavage
is shown below. Percent cleavage was calculated as the ratio of gp120/(gp120+gp160). MWM indicates molecular weight marker lane, with markers shown 181 kDa and 115 kDa.
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the Thr to Ala change at position 569 (Q461e2TAIV, Q461e2TAIA,
Q461e2TAIT), suggesting increased binding compared to the parental
Env. There was little to no detectable binding to 4E10 for cells expres-
sing any of the envelope variants (data not shown), perhaps reﬂect-
ing the poor binding of this MAb to its MPER peptide target when
the Env is in its native, untriggered, membrane-bound conformation
or steric occlusion of the epitope at the cell surface.
Similar patterns of Env expressionwere observed in the cells used for
the gp41-MAb ﬂow cytometry experiment (Fig. 4b) to those used to ex-
amine b12 binding (Fig. 3b). Because the target for binding in this exper-
iment was the gp41, we performed Western blot analysis of the cells
using a cocktail of MAbs that detects various epitopes in Env including
gp41 (Fig. 4c) (Moore et al., 2006). The g41 protein appeared as a dou-
blet, which has been attributed to different glycolsylated forms of
gp41 in prior studies (Phogat et al., 2008). Cells expressing any envelope
with the T569A change had the lowest amount of cleaved Env, ranging
from 22 to 23% of the total Env (Fig. 4c). While the relative amounts of
total Env were generally similar across the virus panel between the
MAb cocktail and the polyclonal rabbit sera primary antibodies, the esti-
mated amount of cleaved Env differed by asmuch as ~2-fold depending
on the antibody used. In some case, a portion of the difference may be
due to saturation of the signal from the uncleaved Env in the Western
analysis using the MAb cocktail, which could lead to overestimates of
the ratio of cleaved to uncleaved Env. Importantly, the overall ﬁndings
are the same with the different antibody probes: the levels of cleaved
Env are consistently lower for variants with the T569A mutation. How-
ever, the magnitude of the difference between the T569A and other var-
iants may be as little as ~2-fold or as much as ~5-fold. These data also
highlight the potential differences in detection of speciﬁc protein vari-
ants depending on the antibody used for analyses (Herrera et al.,
2005; Moore et al., 2006).Characterization of the binding of 4E10 to Q461 peptides using SPR
The I165V change lies within epitope for 4E10, and thus could impact
4E10 binding. To examine the direct effect of amino acid changes at posi-
tion 675 on the binding of 4E10, we performed SPR equilibrium experi-
ments on immobilized peptides spanning the linear 4E10 epitope of
Q461e2 and the IV, IA and IT variants plus four C-terminal lysine residues
added to facilitate coupling (NWFDISKWLWYIKKKK; Fig. S1; (Blish et al.,
2007)). Binding analyses with Fv versus Fab forms of 4E10, representing
independent determinations of the interactions, agreed within ~two-
fold, showing good reproducibility and agreement, consistentwith previ-
ous analyses ((Xu et al., 2010); Table 3 and Figs. S1a and b). 4E10 Fv and
Fab analytes bound to peptides representing the conserved Q461e2 se-
quence, containing an Ile at position 675, no more than ~seven-fold
more tightly than peptides representing any of the neutralization-
sensitive sequenceswith a Val, Ala, or Thr at this position,with the larg-
est differences between the Q461e2 and Q461e2IT peptides. Such small
differences in afﬁnity could easily be accounted for by slight entropic ef-
fects from changes in conformational ﬂexibility (substituting an alanine
forβ-branched residues) or hydrophobicity (substitutingmore polar al-
anine and threonine residues for isoleucine or valine).
Discussion
An understanding of themechanisms of HIV-1 neutralization suscep-
tibility, and how natural genetic variation in HIV-1 affects this process,
are important for rationale design of HIV-1 envelope immunogens. The
studies presented here suggest that two positions (569 and 675) in the
Env gp41 that alter neutralization susceptibility to a range of broadly
neutralizing antibodies do so by inducing changes in Env conformation.
Changes at positions 569 and 675, whichwere ﬁrst identiﬁed among en-
velope variants cloned directly from an infected individual (Blish et al.,
Fig. 4. (A) Flow cytometry analysis of 2F5 binding to cells expressing Q461e2 Env variants. The gray shaded proﬁle denotes ﬂuorescence for cells transfected in the absence of plas-
mid (Mock transfected cells). The color designation for the ﬂuorescence proﬁle for the various Envs is shown within each panel. (B) Western blot of cells expressing the Q461e2-
associated Envs probed with an anti-Env polyclonal rabbit primary Ab. The Env tested in shown above the blot with the parental wild type (WT) Q461e2 indicated; the percent Env
cleavage is shown below. The bands corresponding to gp160 and gp120 are designated. Percent cleavage was calculated as the ratio of gp120/(gp120+gp160). MWM indicates
molecular weight marker lane, with markers shown 181 kDa and 115 kDa. (C) Western blot analysis of the same cell lysates as in panel B using a MAb cocktail. The MAb cocktail
included 1 μg/ml of 2 G12, b12, 2 F5, and 4E10, which recognizes uncleaved Env (i.e., gp160) and cleaved Env (i.e., gp41(Moore et al., 2006)), Designations are as in panel B. MWM
indicates molecular weight marker lane, with markers shown 181 kDa in the upper panel and 48.8 and 37.1 KDa in the lower panel.
240 E. Lovelace et al. / Virology 421 (2011) 235–2442008), had variable impacts on binding to different antibodies. Increased
antibody binding did not always result in increased neutralization sensi-
tivity and increased neutralization sensitivity was not always reﬂected
by increased binding to the epitope target. These ﬁndings support a
model inwhich gp41 changes alter Env conformation to expose a varietyTable 3
KD values for 4E10 Fv and Fab analytes interacting with epitope peptides.
Peptide Fv 4E10 (nM) Fab 4E10 (nM)
e2 20±2 10±1
IV 53±3 25±3
IA 39±2 40±2
IT 71±3 64±3of epitopes on both gp41 and gp120, but in a manner that is not directly
correlated to changes in MAb binding.
A highly conserved Ile at position 675 contributes to a neutralization-
resistant phenotype. A change from Ile to either Ala, Thr or Val increased
susceptibility to the gp41-speciﬁc antibodies 4E10 and 2F5, but did not
affect susceptibility to gp120-directed MAbs, b12, VRC01 or PG9, unless
paired with a second change at position 569. The Ile 675 lies within the
core epitope for 4E10 (NWFN(D)IT(S); (Zwick et al., 2001)), and it is
part of the hydrophobic face that contacts the 4E10 Mab (Cardoso et al.,
2005). However, the dramatic increase (~400-fold) in neutralization sen-
sitivity that results from a change away from Ile is not due to increased
binding afﬁnity for the core epitope, because the amino acid changes at
675 have a very small effect on 4E10 Fv binding to peptide. These results
using quantitative SPR binding analyses suggest that differences in
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differences in binding to the speciﬁc peptide target. Previous studies sug-
gested that neutralization differences also cannot be explained by a pro-
longed exposure of the peptide during fusion (Blish et al., 2008).
Therefore, these ﬁndings support a model in which an amino acid other
than Ile at position 675 causes a conformational change that in some
manner allows better access of a variety of antibodies to their epitopes.
We detected weak binding of 2F5 to Env on the cell-surface, and
there is some evidence that 2F5 binds both the unliganded trimer as
well as a fusion intermediate (de Rosny et al., 2004), although other
studies have not detected 2F5 binding, even to viral Envs thatwere sen-
sitive to neutralization by this Mab (Cavacini and Posner, 2004). There
was a subtle signal suggesting binding of 2F5 to neutralization resistant
variants, including the parental envelope, Q461e2, but the shift in ﬂuo-
rescent signal was less than for variants encoding the Ile 675 changes.
Overall, the data suggest that the change from Ile at position 675 results
in amodest increase in binding to 2F5 that corresponds to a dramatic in-
crease in neutralization sensitivity. However, due to the poor signal to
noise ratio in the 2F5 ﬂow cytometry experiments, we interpret this
ﬁnding with caution.
The Thr to Ala at position 569 is sufﬁcient to permit antibody binding
to gp120, as evidenced by binding to theMAb b12. b12 targets a discon-
tinuous epitope overlapping the CD4 binding pocket in gp120 (Burton
et al., 1994; Roben et al., 1994)). There are no differences in the CD4
binding loop sequence among the variants studied here; all the viruses
differs from the canonical CD4 binding loop sequence at positions 369
and 372, both of which are variable among natural isolates and not di-
rectly linked to neutralization sensitivity(Wu et al., 2009). Thus, differ-
ences in binding cannot be ascribed to differences in the target
sequences that bind to the b12 MAb. Differences in binding are also
not due to differences in the amount of total or cleaved Env on the cell
surface as the T569A variant had similar total Env and lower levels of
cleaved Env compared to Q461e2.
The percentage of uncleaved, gp160 protein was high for the
Q461e2TA variant, 2–5-fold higher than the levels found on cells
expressing variants that did not bind b12 (e.g. Q461e2 and the
I675A/T/V mutants). Because non-neutralizing antibodies can bind
uncleaved envelope (Dey et al., 2009; Pancera and Wyatt, 2005), we
considered the more trivial explanation that the increased binding
to the T569A mutant at least partially reﬂects binding to uncleaved,
non-functional trimers (Herrera et al., 2005; Moore et al., 2006). If
this were the case here, one would expect to see at least some rela-
tionship between the amounts of uncleaved envelope and the extent
of the shift in ﬂuorescence intensity due to speciﬁc antibody binding,
perhaps in addition to the desired read-out of binding due to any spe-
ciﬁc interactions with the cleaved trimer. However, there was no de-
tectable b12 binding to the parental Q461e2 envelope and variants
with changes at 675, even though as much as 51% of the envelope
protein was uncleaved, depending on the antibody used for Western
analysis. Thus, if the increased binding due to the T569A mutation
was simply due to increased levels of uncleaved envelope, we
would expect that there would be detectable b12 binding to all the
Env proteins. This was not the case, and the magnitude of the increase
in ﬂuorescent signal for the Q461e2TA versus the wild-type and 675
mutant envelope proteins do not support the model that increased
binding of b12 to Q461e2TA is simply due to increased amounts of
uncleaved Env. Rather, these data suggest that there is a conforma-
tional effect that results from the T569A amino acid change in the
gp41 that leads to b12 binding to Env expressed on the cell surface.
Studies of Wu et al., 2009 (Wu et al., 2009), demonstrated that the
T569A change, when introduced into a b12-resistant subtype B vari-
ant (CAAN5342.A2), enhanced neutralization sensitivity to b12 and
other MAbs. Thus, the T569A change may impact b12 sensitivity in
the absence of other changes in certain viral contexts, but not in
others (e.g. Q461e2). In the study of Wu et al., it was not possible to
discern the effects of this mutation on Env-b12 binding becauseonly binding to monomeric gp120 was examined, which would not
reﬂect conformational changes contributed by the T569A change in
gp41. However, the ﬁndings that T569A can increase neutralization
sensitivity support the model that this amino acid change may induce
a conformational change that allows antibody access to key b12 bind-
ing residues, resulting in b12 binding to the membrane-associated
form of the envelope protein. In the context of some Env variants,
such as the subtype B virus CAAN5342.A2, this interactionmay be suf-
ﬁcient to promote neutralization. However, in other cases, such as the
subtype A, Q461e2 variant studied here, the T569A may increase b12
binding, but the second mutation at I675 is needed to render the en-
velope sensitive to b12 neutralization. A second, as yet unidentiﬁed
amino acid position in other virus variants, such as the subtype B
virus mentioned above, may be playing a similar role. Interestingly,
the I675 changes alone do not impact either b12 binding or neutrali-
zation. These data therefore suggest that these gp41 changes participate
in a two step process to promote neutralization by b12 antibody — one,
induced by the T569A change, is a conformational change that permits
b12 access to key binding residues; another, which results from a
I675A/T/V change only occurs in the context of the conformational
change induced by the T569A change. For the I675 changes, in the pres-
ence of T569A, but not in its absence, there is both increased binding and
enhanced susceptibility to b12 neutralization.
While the combination of the 569 and 675 changes had a dramatic
effect on neutralization susceptibility to some MAbs and to polyclonal
plasma antibodies from infected individuals, they had less effect on
the more potent MAbs, PG9 and VRC01. Thus, while these two changes
in gp41 may induce conformational changes that have a broad impact
on neutralization susceptibility to a range of antibodies, their effect on
antibody binding and neutralization varies depending on the epitope
target. It is noteworthy that changes in neutralization sensitivity were
not always reﬂected by changes in antibody binding, for example, in
the case of b12, where a change at 569 that increased antibody binding
was needed for the second 675 substitution to affect neutralization sen-
sitivity. It may be that for some virus-antibody combinations, the Env
conformation permits some aspects of this two-step process to occur
in the absence of these amino acid changes. Thus, each change individ-
ually has a more modest effect on neutralization sensitivity. Overall,
these ﬁndings suggest that antibody neutralization likely involves
higher-order conformational changes that result from multiple amino
acid changes in envelope acting in concert, only some of which directly
impact antibody binding.
Materials and methods
Cloning and generation of HIV-1 viral envelope proteins
The full-length env clone Q461e2 was ampliﬁed directly from pe-
ripheral blood mononuclear cells from a Kenyan woman at 28 days
post-infection (Long et al., 2002). The Quik-Change site-directed muta-
genesis kit (Stratagene) was used to create Q461e2 envmutants using
primers containing the desired mutations that encode amino acid
changes at positions 569 and 675. Clones were sequenced to identify
those that had solely the desired change and these were used in subse-
quent experiments.
Plasma samples and antibodies
Theplasmapoolwas generated bypoolingplasma collected between
1998 and 2000 from 30 HIV-1-positive individuals in Mombasa, Kenya
(Blish et al., 2007). The MAbs used in the neutralization and ﬂow cyto-
metry experiments were as follows: 2F5 and 4E10 were provided by
Hermann Katinger (Polymun Scientiﬁc, Vienna, Austria), and b12 was
provided by Quality Biological Inc. (Gaithersburg, MA). PG9 was kindly
provided by Dennis Burton and the IAVI team, VRC01 by John Mascola,
and the rabbit polyclonal antisera generated to HIV-1 Env (Doria-Rose
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and Science University).
Generation of pseudoviruses and infectivity assays
HIV-1 env clones, as well as SIVMne Clone 8 env (Pineda et al., 2007),
were used to generate pseudoviral particles by cotransfection of 293T
cells with the viral plasmid containing the env of interest and Q23Δenv
(Long et al., 2002; Poss and Overbaugh, 1999) DNA, a subtype A HIV-1
proviral clone with a partial deletion in env. Transfections were per-
formed using polyethylenimine (PEI; Polysciences, PA), and Q23Δenv
DNA preparations were used at a 20:1 w/w backbone/env ratio to com-
plement the env expression plasmids and create pseudovirus, as previ-
ously described (Blay et al., 2007). After 48 hours, viral supernatants
were harvested through a 0.22 μm sterile ﬁlter and infectious titers
were determined by infecting TZM-bl cells (NIH AIDS Research and Ref-
erence Reagent Program) in the presence of 10 μg/ml DEAE-dextran
(Sigma) (Vodicka et al., 1997). All pseudoviral supernatants were con-
centrated prior to aliquoting using an Amicon Ultra centrifugal 100 kDa
MWCO cellulose membrane ﬁlter device (Millipore), typically resulting
in a four-fold increase in viral titer.
All neutralization assays were performed in triplicate with at least
two independent preparations of pseudoviral stock, as previously de-
scribed (Blish et al., 2007; Wu et al., 2006)). Median inhibitory con-
centrations (IC50s) were deﬁned as the concentration of MAb or the
reciprocal dilution of plasma pool stock that resulted in 50% inhibi-
tion, calculated as described (Blish et al., 2007; Wu et al., 2006).
When the virus was not neutralized to 50% at the highest neutralizing
antibody concentration tested, the highest concentration tested
(25 μg/ml) was used for calculating the mean IC50.
Flow cytometry analysis
Cells expressing the relevant Env variant were generated by trans-
fecting 293T cells with the viral Env DNA. Brieﬂy, 4×106 cells were seed-
ed the day before transfection, transfected with PEI and 12 μg of HIV-1
env DNA, replaced by mediumwithin 16 h, and cells were harvested ap-
proximately 72 hours post-transfection. To stain cells forﬂow cytometry,
cells were resuspended in wash buffer (WB; 2% fetal bovine serum in
PBS; Gibco) then incubated at 37 °C for 60 min in primary antibody
(e.g., MAb or plasma pool) at a ﬁnal concentration of 20 μg/ml. Following
primary antibody incubation, cells were washed and incubated at 37 °C
for 40 min with secondary antibody, goat-anti-human IgG-PE (Santa
Cruz Biotech, US), at a 1:100 dilution. Cells were rewashed, resuspended
in 1% paraformaldahyde to ﬁx, and stored at 4°°C in the dark until ﬂow
cytometry processing. All ﬂow cytometry was performed on Becton-
Dickinson FACS Calibur and data was analyzed using FlowJo software.
Quantiﬁed western blotting of pseudoviral envelope and envelope-
expressed 293Ts
Puriﬁed pseudoviral preparationswere prepared forWestern blotting
using amodiﬁcation of a previously describedprotocol (Blish et al., 2007).
The amount of virus usedwas normalized based on titer deﬁned by infec-
tivity in TZM-bl cells. Brieﬂy, pseudoviral supernatants were pelleted by
microcentrifugation at 16,000 g for 60 min at 8 °C and the viral pellet
was resuspended in lysis buffer (1% Triton X-100 [Sigma]/PBS) to ablate
viral infectivity. Samples were then boiled at 100 °C for 10 min, immedi-
ately put on ice, and then stored at −20 °C. Prior to loading on the gel,
sampleswere thawed, thoroughlymixedwith SDS loading buffer and re-
ducing agent (Invitrogen), followed by an additional 10 min boil to en-
sure complete protein denaturation. Samples were resolved on a 4–12%
gradient Bis-Tris polyacrylamide gel (Invitrogen), followed by electro-
transfer to a nitrocellulosemembrane. A dilution of 1:8000 of rabbit poly-
clonal antisera generated to HIV-1 Env (Doria-Rose et al., 2005)was used
as a primary antibody and IRDye700DX-conjugated goat-anti-rabbit IgGat a dilution of 1:15,000was used as a secondary antibody (Rockland Im-
munochemicals). A cocktail of MAbs 4E10, 2F5, 2G12, and b12 at 1 μg/ml
were used as primary antibodies (modiﬁed from (Moore et al., 2006))
and IRDye800DX-conjugated goat-anti-human IgG at a dilution of
1:8000 was used as a secondary antibody (Rockland Immunochemicals).
To determine p24 levels, mouse anti-p24 (cat. no. 4121; NIH AIDS Re-
search and Reference Reagent Program) was used as a primary antibody
and IRDye800DX-conjugated goat-anti-mouse IgG was used as a second-
ary antibody (Rockland Immunochemicals).Westernblotting andprotein
quantiﬁcation was performed using the Odyssey infrared imagining sys-
tem (LI-COR Biosciences), which has a large dynamic detection range.
Percent cleavage was calculated as amount of gp120 signal/total
amount of Env signal (both gp160 and gp120)×100. The fold-difference
between an envelope variant compared to the wild type parental Env
Q461.e2was deﬁned as the amount of gp120 for that variant Env/amount
of gp120 for the wild type, Q461e2.
SPR analyses of the interactions between Fab or Fv 4E10 against peptide
Protein/peptide interaction analyses by surface plasmon resonance
(SPR) were conducted at 25 °C in HBS-EP buffer (Biacore AB) on a Bia-
core T100 system. For analyses of the binding of 4E10 Fv and Fab analytes
to peptides corresponding to the 4E10 epitope in clade A Q461e2 env
variant (wild type and mutants; Table 3), peptide at 10 to 50 μg/ml in
10 mM sodium acetate (pH 5.0) was covalently immobilized on a CM5
research-grade sensor chip (Biacore AB) by standard amine coupling
chemistry following the manufacturer's protocols; reference ﬂow cells
were left blank. Four C-terminal lysine residues were added to each pep-
tide sequence to aid coupling and match peptides used in prior studies
(Cardoso et al., 2007; Xu et al., 2010). Immobilization of ~200 to 270 re-
sponse units (RU) resulted in optimal responses in subsequent analyses.
Different concentrations of 4E10 Fv or Fab analytes were injected in ran-
domized duplicate runs, at a ﬂow rate of 10 μl/min for 180 s to reach
equilibrium, followed by a 120 second dissociation phase. Regeneration
of the sensor chip was achieved by injection of 10 mM glycine
(pH=1.5) at a ﬂow rate of 20 μl/min for 6 s followed by HBS-EP buffer
stabilization for 180 s. Sensorgrams obtained from SPR measurements
were blank-corrected by the double-referencing method (Myszka,
1999). Equilibrium dissociation constants (KD) were estimated by plot-
ting steady-state binding levels of 4E10 Fv or Fab analytes on sen-
sorchip-coupled epitope peptides against analyte concentrations with
BIAevaluation 2.0 software (Biacore AB). Other anti-HIV-1 MAbs were
also tested for binding to immobilized Q461e2 peptides, with nomeasur-
able responses for 800 nM Fab 447 or 800 nM Fab b12 analytes, showing
the speciﬁcity of the 4E10 responses (data not shown).
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.09.032.
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